Breaks Categories: Stock Spotlights

WednesdayFeb 01, 2017 1:34 pm

NetworkNewsBreaks – Westell Technologies, Inc. (NASDAQ: WSTL) Targets Industry Poised for $486M; “Future-proof” PS71090 Slated for Release Q1 2017

Since its founding in 1980, Westell Technologies (NASDAQ: WSTL) has expanded and acclimated to the evolving, high-performance wireless infrastructure solutions industry, offering today’s most technologically advanced in-building wireless, intelligent site management, cell site optimization and outside plant solutions. In November, the company announced the newest member of its in-building wireless coverage solutions portfolio, PS71090 Signal Booster. The “future-proof” solution was designed to meet the strict requirements of the National Fire Alarm Code NFPA 72 standards, as well as the anticipated First Responder Network Authority (FirstNet) requirements. The PS71090 is expected to be generally available in the first quarter of 2017,…

Continue Reading

WednesdayFeb 01, 2017 1:31 pm

NetworkNewsBreaks – First Choice Healthcare Solutions, Inc. (FCHS) – Transforming Healthcare Delivery for Doctors and Patients

Quality and distinction matter at First Choice Healthcare Solutions (OTCQB: FCHS). Indeed, the company’s model for success is based on the premise that doctors get to be doctors at its Medical Centers of Excellence and, consequently, patients get excellent “personalized” care. A talented team of healthcare experts and executives are at the helm at First Choice, leveraging a shared vision and tested experience to steer the company’s patient-centric culture, daily operations, smart growth strategies, and long-term value creation. With their guidance, the company is developing its Centers into superior clinical destinations that will offer more significant and collaborative doctor-patient interactions,…

Continue Reading

WednesdayFeb 01, 2017 1:29 pm

NetworkNewsBreaks – Atossa Genetics, Inc. (NASDAQ: ATOS) Targets Breast Cancer with Patented Intraductal Microcatheters; Several Patent Applications Pending

Atossa Genetics (NASDAQ: ATOS) is a clinical-stage pharmaceutical company focusing on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. In 2015, an estimated 231,840 women in the United States were diagnosed with invasive breast cancer, and an estimated 60,000 U.S. women were diagnosed with non-invasive in situ carcinoma. Of those, approximately 40,000 women died from breast cancer. The company’s leading program uses its patented intraductal microcatheters that deliver pharmaceuticals through the breast milk ducts, which may provide a higher concentration of the therapeutic to the target tissue. In March 2016, a phase 2 clinical…

Continue Reading

WednesdayFeb 01, 2017 1:26 pm

NetworkNewsBreaks – Vericel (NASDAQ: VCEL) Shares Tick Higher; First U.S. Patient Receives MACI Implant to Treat Cartilage Defects of the Knee

Vericel (NASDAQ: VCEL) is up 4% mid-day after the company said the first patient in the United States has received the MACI® implant. MACI® is an autologous cellular scaffold product that is indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The MACI implant consists of human-derived cells (obtained from the patient's cartilage) seeded onto a resorbable type I/III collagen membrane. "We believe that the simplified MACI surgical technique, together with the MACI phase 3 clinical data demonstrating statistically significantly greater improvement in pain and function scores…

Continue Reading

WednesdayFeb 01, 2017 11:16 am

NetworkNewsBreaks – ChineseInvestors.com (CIIX) Launches ChineseCBDoil.com Website; Featured in Interview Outlining Entry into Cannabis Industry

ChineseInvestors.com (OTCQB: CIIX) has launched a new website for its ChineseCBDoil.com subsidiary, through which CIIX is expanding into the medical marijuana industry. The site is an online retailer of hemp oil and related products, which are legal to sell and distribute within China as well as in the United States. “Our expertise in online communications with our background in media, technology, and journalism, via our http://www.Chinesefn.com website will further enhance our success,” CEO Warren Wang stated in the news release. “Our core business, the online distribution of news to the Chinese speaking population about financial markets and stocks has been…

Continue Reading

TuesdayJan 31, 2017 11:45 am

NetworkNewsBreaks – eXp World Holdings, Inc.’s (EXPI) Unique Operations Support Environmental Sustainability

eXp World Holdings’ cloud-based real estate brokerage has many benefits for the company itself, but the perks of its structure help the environment as well.  “Companies such as eXp World Holdings, Inc. (OTCQB: EXPI) are completely changing the way the real estate industry itself functions. Gone are the days during which agents and brokers were expected to work in a brick and mortar office. EXPI has not only cut unnecessary expenses and built an agent-owned, cloud-based real estate brokerage that operates without the need for offices, utility bills, insurance, furnishings and redundant staffing costs, the company has correspondingly cut its…

Continue Reading

TuesdayJan 31, 2017 11:41 am

NetworkNewsBreaks – Sorrento Therapeutics, Inc. (NASDAQ: SRNE) Enriching Lives through Scientific Innovation

California-based biopharmaceutical company Sorrento Therapeutics (NASDAQ: SRNE) has a portfolio of OnTarget immunotherapies comprised of intracellular antibodies, immune checkpoint inhibitors, bispecific antibodies, and antibody-drug conjugates, as well as chimeric antigen receptor (CAR)-based cellular therapies. Through its TNK Therapeutics subsidiary, the company is also advancing adoptive cellular therapies utilizing the T cell as well as the Natural Killer cell. Sorrento has partnered with the City of Hope to form a joint venture, LA Cell, which is developing cell-internalizing mAbs against undruggable intracellular targets. Sorrento’s lead programs are four late-stage biosimilar and biobetter antibodies targeting an established market of more than $13…

Continue Reading

TuesdayJan 31, 2017 11:35 am

NetworkNewsBreaks – Amyris, Inc. (NASDAQ: AMRS) Making Technological Breakthroughs Under Guidance of Highly Experienced Management Team

Amyris (NASDAQ: AMRS) is one of the fastest growing industrial biotechnology companies among the 2,772 in the U.S today. The company’s seven-person management team is made up of hand-picked individuals with a proven ability to innovate and build companies in a number of industries. With over 30 years of experience as a tech entrepreneur and thought leader, president and CEO John Melo has led Amyris from technology development and industrial startup to product development and final commercialization. Thanks to the team’s level of experience, Amyris has made outstanding technological breakthroughs, among these is the world’s leading treatment for malaria, saving…

Continue Reading

TuesdayJan 31, 2017 11:33 am

NetworkNewsBreaks – Provision Holding (PVHO) Positioned as Leading Purveyor of 3D Holographic Technology

Provision Holding (OTC: PVHO) provides three-dimensional (3D) holographic display technologies, software and integrated solutions for both commercial and consumer-focused applications. Provision’s patented, interactive displays are built on proprietary technology to deliver “3D Holographic Media” – without the use of special glasses – to target audiences. The company’s early line of display systems is ideally suited for indoor and outdoor point-of-sale, merchandising and point of sale-related advertising venues. Recently, the company launched version 2.0 of its advanced 3D Savings Center software. The application-based platform delivers a comprehensive solution to consumers in retail stores while remaining user-friendly with an enhanced loyalty card…

Continue Reading

TuesdayJan 31, 2017 11:30 am

NetworkNewsBreaks – Strong IP, Key Partnerships Drive RegeneRx Biopharmaceuticals, Inc. (RGRX) Growth

RegeneRx (OTCQB: RGRX) is a clinical-stage biopharmaceutical company with a large, growing patent portfolio that protects multiple indications and applications for its product candidates. At the heart of its IP strategy is Thymosin Beta 4 (Tβ4), a naturally occurring peptide found to play a vital role in protection, regeneration and remodeling of damaged tissues. RegeneRx is currently moving three distinct Tβ4-based drug candidates through clinical development for ophthalmic, cardiac and dermal indications. The company recently received notice of Intent to Grant a patent from the European Patent Office for treating neural injury using Tβ4. More recently, the company received patent…

Continue Reading